A clinical trial involving 1,200 adults evaluated the safety of standardised ashwagandha root extract. Participants took either ashwagandha or a placebo for 24 weeks without adverse effects on liver or kidney function. The study monitored participants' immune responses following COVISHIELD vaccination. Results indicated that ashwagandha did not impact virus-neutralising activity compared to the placebo group. This trial adds to the evidence supporting the safety of Ayurveda interventions.